Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
DILACOR XR is a brand-name extended-release oral capsule formulation of an undisclosed active pharmaceutical ingredient approved as a small-molecule NDA in 1992. The specific indication, mechanism of action, and pharmacologic class are not provided in available data. Patient population and therapeutic use cannot be determined without additional clinical information.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely consolidating resources or transitioning to lifecycle management mode rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
DILACOR XR currently has zero linked job openings, reflecting its LOE-approaching status and limited commercial activity. Joining this product team would position you in a maintenance/legacy management role rather than a growth or launch environment, with emphasis on defending market share against generics and optimizing profitability.
Worked on DILACOR XR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.